 Home > Biochemistry News > Biotechnology News > Two immune combination therapies for the first-line treatment of esophageal cancer and BMS are expected to add additional indications

Two immune combination therapies for the first-line treatment of esophageal cancer and BMS are expected to add additional indications

 Last Update: 2021-10-23
 Source: Internet
 Author: User

Tags

types food dinner

food safety standards

k3 drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 27, 2021, Bristol Myers Squibb (Bristol Myers Squibb) announced that based on the positive results of the Phase 3 clinical trial, the US FDA has accepted its PD-1 inhibitor nivolumab and CTLA-4 inhibitor Iraq.

Nivolumab (Nivolumab, the English trade name is Opdivo) targets PD-1, which can help the body restore the anti-tumor immune response

This application is based on the results of a pivotal Phase 3 clinical trial.

Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer deaths in the world.

Reference materials:

[1] US Food and Drug Administration Accepts Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express first-line treatment of esophageal cancer, two immune combination therapies of BMS are expected to add additional indications

10-11

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Two immune combination therapies for the first-line treatment of esophageal cancer and BMS are expected to add additional indications

Related Articles

Express first-line treatment of esophageal cancer, two immune combination therapies of BMS are expected to add additional indications